All material subject to strictly enforced copyright laws. © 2022 Euromoney Institutional Investor PLC group
LevFinLevFin High Yield Bonds

Teva prepares to term out funding but opioid problems weigh on costs

Teva lab

Generic pharmaceuticals firm Teva has released price thoughts for a $1.5bn bond refinancing, which will term out its maturities. But the levels on offer show potential opioid litigation is still weighing on the firm’s capital structure. The Israeli company settled with a group of US states at the end of October, sending its shares and bonds surging, but the firm faces a trial in New York next March.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree